Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-2 With or Without LMI Vaccine in Stage IV Melanoma
NCT00726739Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Jun 2008
- Primary completion
- Jun 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of LP2307 in melanoma (2 arms), sponsored by Masonic Cancer Center. Primary endpoint: Progression-Free Survival at 2 years. Started Jun 2008; status: completed.
02
Drugs
LP2307
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00726739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00726739.